Promoting biosimilars up to health plans, manufacturers, doctors, Gottlieb says

Center for Biosimilars

21 March 2019 - As he wraps up his final weeks as commissioner of the FDA, Scott Gottlieb, MD, talked about the factors holding back biosimilars in the United States.

Scott Gottlieb is trying to wrap up loose ends as he prepares to leave what he described as “the best job I’ll ever have,” but he implied the FDA’s role is somewhat constrained in terms of trying to promote acceptance of biosimilars during an interview this week hosted by the Hutchins Center on Fiscal & Monetary Policy and the USC-Brookings Schaeffer Initiative for Health Policy at the Brookings Institution.

The outgoing commissioner was asked by Anna Edney, a Bloomberg News reporter, if the FDA, or the government, can do anything about patent thickets. Last week, HHS Secretary Alex Azar appeared before the Senate Finance Committee and said that “ending anticompetitive practices that delay or restrict biosimilar market entry” is part of the administration’s plan to lower the cost of prescription drugs.

Read Center for Biosimilars article

Michael Wonder

Posted by:

Michael Wonder